Effects of BCc1 nanoparticle and its mixture with doxorubicin on survival of murine 4T1 tumor model

Maryam Hafizi1,2
Masoud Soleimani3
Sajad Noorian4
Somayeh Kalanaky2
Saideh Fakharzadeh2
Nafiseh Tavakolpoor Saleh5
Mohammad Hassan Nazaran2,6
Mohammad Esmaeil Akbari1,6

1Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Department of Research and Development, Sodour Ahzar Sharigh Company, Tehran, Iran; 3Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; 4Department of Statistics, Faculty of Sciences, University of Qom, Qom, Iran; 5Stem Cell Technology Research Center, Tehran, Iran

*These authors contributed equally to this work

Background: Our previous findings showed that BCc1, a nanoparticle designed based on nanochelating technology, can be considered a new anti-cancer nanoparticle if confirmed by complementary studies.

Goal: In the present study, we investigated the effects of the BCc1 nanoparticle alone on some gene expressions influencing the apoptosis pathway, and also the effect of the mixture of BCc1 nanoparticle and doxorubicin on survival.

Method: Using an in vitro study, the effects of the BCc1 nanoparticle on Bax, Bcl2, p53, Caspase7 and p21 gene expressions were assessed after a 24-h treatment using real-time PCR in MCF-7 and MEFs; in addition, using an in vivo study, 4T1 tumor-bearing female Balb/c mice were treated with different doses of the BCc1 nanoparticle and doxorubicin alone and together and then their mean and median survival was evaluated.

Result: The results showed that the BCc1 nanoparticle increased gene expressions of RB, p53, Caspase7, p21, and Bax and decreased gene expressions of Bcl2 in MCF-7 significantly, but no change was observed in MEFs expressions. The findings revealed that the BCc1 nanoparticle, when used orally, had the highest mean and median survival time. A mixture of a high dose of the BCc1 nanoparticle (1 mg/kg) and a low dose of doxorubicin (0.1 mg/kg) showed synergistic effects on enhanced life span, while doxorubicin dose was prescribed approximately 50 times less than the murine applicable dose (5 mg/kg).

Conclusion: Our results demonstrated that the BCc1 nanoparticle not only has the potential to become a novel nanomedicine for cancer therapy, but it can also provide the basis of a new medicine for cancer management when mixed with a lower applicable dose of doxorubicin.

Keywords: BCc1 nanoparticle, cancer, doxorubicin, nanochelating technology, murine 4T1 tumor model

Introduction

In the next 20 years, the number of new cancer cases is forecast to increase by almost 70%.1,2 To date chemotherapy has been considered a standard treatment for all kinds of cancers; however, the outcomes of this kind of treatment are not desirable enough, so in recent years, by shedding more light on molecular pathways, tumor biology, tumor–host interactions and tumor microenvironment, new combination therapies3–5 including chemotherapy with targeted therapy, chemotherapy with immunotherapy and chemotherapy with gene therapy have been developed.6

Doxorubicin, an antineoplastic agent, has been widely used, either alone or in combination with other chemotherapy drugs, as a chemotherapeutic agent since the
However, the clinical use of this drug is harmful due to its damaging effects on heart, hepatotoxicity, hematologic index, etc. Nowadays, researchers aim to find some compounds that are able to neutralize the toxic effect of doxorubicin, while maintaining the antitumor effect of the drug. To achieve this, doxorubicin is administered in a liposomal formulation, permitting patients to be treated with higher lifetime doses. Additionally, well-tolerated doxorubicin can be beneficial to a great extent combined with other regimens in order to enhance tolerability or allow the combination partners to be delivered at higher doses.

Nanotechnology envisages a breakthrough in the domain of cancer therapy owing to its unique properties and functions. This technology is completely flexible as it permits scientists to engineer drug nanoparticles of dimensions 10–500 nm, enabling them to pass through the leaky vasculature of the tumorigenic microenvironment with higher specificity and reduced cytotoxicity.

Nanochelating technology, a new branch of nanotechnology, has recently proved its noticeable impact in various sciences by synthesizing unique nanostructures. In our previous report, MSc1 nanocomplex, synthesized by nanochelating technology, exhibited therapeutic effects in an animal model of multiple sclerosis. Also, in an experimental model of Parkinson disease, Maghsoudi et al revealed neuroprotective effects of three nanochelating-based nanocomplexes. According to our other experiments, GFc7 nanocomplex (an iron-containing copper chelator nanocomplex) improved cell proliferation in addition to maintaining and increasing pluripotency properties of Human Mesenchymal Stem Cells (HMSC).

Using an in vitro study, we have already investigated the anticancer effects of the BCc1 nanoparticle (45–47 nm), designed based on nanochelating technology by a self-assembly method, and the results demonstrated that although BCc1 nanoparticle cell toxicity was higher for cancer cells than normal ones, it did not affect the viability of healthy cells at a fixed concentration and could increase the percentage of early and late apoptosis in cancer cells as compared to control. Likewise, the G1 phase percentage increased from 59% to 70%, while S and G2/M phases percentages decreased from 15% to 12% and 26% to 18%, respectively. Additionally, the report of our in vivo study showed that the BCc1 nanoparticle led to an increase in survival and decrease in the growth of tumor size in breast cancer-bearing Balb/c mice without anemia.

Nowadays, many tumor suppressor genes are found to be effective in cell cycle control. Tumor suppressor genes usually prevent or reduce the likelihood of malignant transformation. However, a tumor suppressor gene efficiency loss puts a cell at risk of neoplastic transformation.

Previous studies have revealed the function of various tumor suppressor genes in cells. P53, nicknamed the “guardian of the genome,” is proven to be vital to cell division control. It takes part in the cell cycle checkpoint pathway and apoptosis and also controls multiple genes, including p21, associated with G1 phase arrest. Similarly, it is also confirmed that cyclin-dependent kinase inhibitor p21 develops cell cycle arrest in response to various stimuli and prevents cellular proliferation independent of CDK2, needed for S phase progression. The retino blastoma (RB) functions to prevent excessive cell growth by controlling cell cycle progression until a cell is ready to divide; therefore, its dysfunctionality is the cause of some major cancers.

The balance between the pro-apoptotic gene Bax and anti-apoptotic gene B-cell lymphoma 2 (Bcl-2) is crucial in cell development, and abnormal expression of Bax and Bcl-2 sets off apoptosis through the mitochondrial pathway. Some other studies have proven the key role of Caspase7 in mediating apoptosis and association between Caspase family members and cancer risk.

In the present study, we investigated cancer and normal cells treatment by the BCc1 nanoparticle so as to compare tumor suppressor gene expressions in both kinds of cells considering the fact that BCc1 nanoparticle can cause apoptosis, so we opted for some genes that affect the apoptosis pathway, such as RB, Bax, Bcl2, p53, Caspase7, and p21, described above.

Moreover, we intended to investigate the effect of oral dose of the BCc1 nanoparticle on survival in metastatic animal modeling and also the effect of a mixture of doxorubicin and BCc1 nanoparticle on survival when used through injection where doxorubicin was applied in a murine applicable dose (5 mg/kg) and a low dose (0.1 mg/kg) as well; that is, 50 times less than its murine applicable dose. Mice mammary carcinoma cells (4T1) were selected for animal modeling as this is a metastatic cell line that can attack liver, lung and brain tissues by rapid cell division.

Materials and methods
Chemicals
The BCc1 nanoparticle was obtained from (Tehran, Iran). DMEM, FBS, PBS, penicillin G, streptomycin (100 mg/
mL), and 0.25% trypsin–ethylene diamine tetraacetic acid were from Gibco-Life Technologies (Carlsbad, CA, USA). Doxorubicin HCl liposome was from Sobhan Oncology (Tehran, Iran).

**BCc1 nanoparticle**

BCc1 nanoparticle with antineoplastic effect, which is a new product patented as “Nanochelating Technology” in the US Patent and Trademark Office (USPTO), was synthesized according to the protocol explained in the previous study.

**Cell culture conditions**

The 4T1 cell line, mouse embryonic fibroblasts (MEFs), and Michigan Cancer Foundation-7 (MCF7) cell line were prepared from the National Cell Bank of Pasteur Institute (Tehran, Iran) and were cultured in DMEM supplemented with 10% FBS, penicillin G, and streptomycin.

MEFs and MCF-7 cells were cultured in a humidified incubator in an atmosphere of 95% air and 5% CO2 at 37°C and seeded onto 6-well plates in triplicate wells, while the cells were maintained with a fresh medium containing BCc1 nanoparticle for 24 h and then p53, p21, Bax, Bcl2, Caspase7, and RB gene expressions were investigated.

**Gene transcription evaluation**

Total RNA was extracted using trizol following the manufacturer’s instructions. Synthesis of cDNA was performed with M-MuLV reverse transcriptase and oligo primers. Gene quantification & real time PCR quantification (qRT-PCR) analysis was conducted using a standard SYBR Green PCR kit protocol on a Rotor Gene 6000 instrument. Data were normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the endogenous control gene. The relative mRNA expression levels were measured according to the ΔCT method.

**Cell viability assessment**

Staining solution, containing propidium iodide (PI) as a reverse indicator of cell viability, was added to the cells and incubated for 1 min in the dark. Following that, PI was assessed by flow cytometry analysis (FACS) to quantify the exact number of cell viability.

**Animals and ethics approval**

Seven-to-eight-week-old inbred female Balb/c mice were purchased from Pasteur Institute, Tehran, Iran. All mice were maintained in large group houses where they were accustomed for 1 week before the test and kept at standard conditions during the study; 24±2°C temperature, 50±10% relative humidity, and 12 h light/12 h dark cycle.

This animal study was conducted according to the relevant national and international guidelines of Shahid Beheshti University of Medical Sciences for the care and use of laboratory animals. It has also received the ethics approval of Shahid Beheshti University of Medical Sciences, Tehran, Iran; Reg. No. IR.SBMU.REC.1396.2.

**Animal experiment and treatment groups**

Before 4T1 cell line was injected to mice, the percentage of cell viability was measured and then 6×10⁵ of cells were suspended in 100 μL of PBS and injected into the second mammary fat pad of female Balb/c mice. During the test, the mice were monitored once every three days after injection and then tumor tissues became noticeable after almost 10 days. Following that, the mice were randomly divided into 10 groups, with 8 in each. All groups were treated via IP injection except one which was treated orally.

The dates on which mice died and their other observable symptoms were investigated and recorded; the sick and moribund animals were excluded from the study. Subsequently, means and medians for survival time of the animals were calculated.

Treatments were categorized according to Table 1, where doxorubicin applicable dose (5 mg/kg) and low dose (0.1 mg/kg) were used orally.

| Groups | Treatments | Dosage |
|--------|------------|--------|
| Group 1 | Control | Distilled water |
| Group 2 | BCc1 nanoparticle low dose | 0.1 mg/kg/once a day |
| Group 3 | BCc1 nanoparticle high dose | 1 mg/kg/once a day |
| Group 4 | Doxorubicin low dose | 0.1 mg/kg/once a day |
| Group 5 | Doxorubicin applicable dose | 1 mg/kg/once a week |
| Group 6 | Mixture of BCc1 nanoparticle (low dose) and doxorubicin (low dose) | 0.1 mg/kg/once a day and 0.1 mg/kg/once a day |
| Group 7 | Mixture of BCc1 nanoparticle (high dose) and doxorubicin (applicable dose) | 1 mg/kg/once a day and 5 mg/kg/once a week |
| Group 8 | Mixture of BCc1 nanoparticle (low dose) and doxorubicin (applicable dose) | 01 mg/kg/once a day and 5 mg/kg/once a week |
| Group 9 | Mixture of BCc1 nanoparticle (high dose) and doxorubicin (low dose) | 1 mg/kg/once a day and 0.1 mg/kg/once a day |
| Group 10 | BCc1 nanoparticle used orally | 10 mg/kg/once a day |
kg), and BCc1 nanoparticle high dose (1 mg/kg) and low dose (0.1 mg/kg) were prescribed for the present study.

**Statistical analysis**

Summary statistics of the data were reported as mean ± standard error from at least 3 separate experiments conducted in triplicate, and means and medians for survival time were presented for all groups. In each group, the standard error and 95% confidence interval were reported for each of these indices.

Survival table for tracking dead time was obtained, yet not reported here. To compare the survival time between these groups, the well-known log-rank test was used as well as the Breslow and Tarone–Ware tests. For pairwise comparison (to know which 2 groups were different), the Wilcoxon test was employed, where the significance level was considered 0.05.

Survival analysis was conducted using life tables and the Kaplan–Meier method and statistical data analysis was computed using the SPSS Statistics version 25 software (IBM, Armonk, NY, USA).

**Results**

**Tumor suppressor gene expressions**

As shown in Figure 1, the gene expressions of Bax in MEFs and MCF-7 were 0.84±0.012 and 1.77±0.015, respectively, and gene expressions of Bcl2 in MEFs and MCF-7 were 0.75±0.1 and 0.91±0.1. Therefore, the BCc1 nanoparticle significantly increased ratio of Bax/Bcl-2 in MCF-7 in comparison with MEFs.

As shown in Figure 2, the gene expressions of p21 in MEFs and MCF-7 were 0.72±0.05 and 2.03±0.1, respectively, and the gene expressions of p53 in MEFs and MCF-7 were 0.63±0.08 and 1.15±0.1. Moreover, the gene expressions of Caspase7 in MEFs and MCF-7 were 0.56±0.05 and 1.76±0., respectively, and the gene expressions of RB in MEFs and MCF-7 were 0.57±0.06 and 1.61±0.17. Thus, these results show that tumor suppressor gene expressions (p21, p53, Caspase7, and RB) significantly increased after BCc1 nanoparticle treatment in MCF-7 cells as compared to MEF cells.

**Cell viability**

PI cannot enter viable cells; however, it can permeate cell membranes of dying or dead cells. In this study, PI was utilized to assay cell viability by flow cytometry to quantify the exact percentage of viable cells compared to initial cultured cells as control. The percentage of cell viability for 4T1 cell line before injecting the Balb/c mice was equal to 98±1% (Figure 3).

**Survival analysis in defined groups**

- **Median survival time**

In Table 2, the median survival time in each group is given. According to this table, the median survival time

![Figure 1](image1.png)

**Figure 1** Effects of BCc1 nanoparticle on the relative expression level of Bax and Bcl2 genes in MCF-7 compared with MEF cells. The black horizontal line shows the onefold enrichment cutoff criteria; data are expressed as mean ± SD; asterisks show datasets that are significant at different levels: *p<0.05, **p<0.01, ***p<0.001.

**Abbreviations:** MEF, mouse embryonic fibroblast; MCF7, Michigan Cancer Foundation-7.
in each group was as follows: control group: 19 days (95% CI: 11.30–26.69); BCc1 nanoparticle group (BCc1 used orally): 38 days (95% CI: 33.1–42.8); BCc1 nanoparticle low dose group: 21 days (95% CI: 18.6–23.4); BCc1 nanoparticle high dose group: 14 days (95% CI: 4.3–23.6); doxorubicin low dose group: 12 days (95% CI: 9.43–14.56); and BCc1 nanoparticle high + doxorubicin low dose group: 34 days (95% CI: 23.7–44.2).

In this table, the p-value for pairwise comparisons with respect to the control group is provided. Accordingly, the groups (BCc1 nanoparticle high + doxorubicin low and BCc1 nanoparticle, used orally) had different survival distributions with respect to the control group. Thus, the results showed that in the groups which used BCc1 nanoparticle orally and the mixture of BCc1 nanoparticle high + doxorubicin low dose, the median survival times were 19 and 15 days significantly higher than the control group, respectively. The values of Wilcoxon statistics for these 2 comparisons were 4/592 and 4/198 with p-value equal to 0.032 and 0.40, respectively.

- Mean survival time

The mean survival times in each group are given in Table 3. According to this table, the mean survival time in each group was as follows: control group: 19.5 days (95% CI: 12.3–26.84); BCc1 nanoparticle group (BCc1 used orally): 35.33 days (95% CI: 27–43.65); BCc1 nanoparticle low dose group: 20.33 days (95% CI: 14.16–26.50); BCc1 nanoparticle high dose group: 23.33 days (95% CI: 19.50–27.16).
15.16 days (95% CI: 7.15–23.17); doxorubicin low dose group: 20.14 days (95% CI: 9.16–31.11); and doxorubicin applicable dose group: 20.14 days (95% CI: 15.18–25.10). Also, the mean for survival time in each mixture group was as follows: BCc1 nanoparticle low + doxorubicin low dose group: 21.42 days (95% CI: 12.44–30.40); BCc1 nanoparticle high + doxorubicin applicable dose group: 16 days (95% CI: 7.96–24.03); BCc1 nanoparticle low + doxorubicin applicable dose group: 12.85 days (95% CI: 9.19–16.52); and BCc1 nanoparticle high + doxorubicin low dose group: 32 days (95% CI: 25.41–38.58).

Thus, the results showed that in the groups which used BCc1 nanoparticle orally, and the mixture of BCc1 nanoparticle high + doxorubicin low dose, the mean survival times were higher than in the control group.

The plots of hazard and survival functions of all groups are given in Figures 4 and 5, respectively.

### Table 2 Median survival time

| Number | Groups                                           | Estimate | Standard error | Lower bound (95% CI) | Upper bound (95% CI) | Significance |
|--------|--------------------------------------------------|----------|----------------|-----------------------|-----------------------|--------------|
| 1      | Control                                          | 19       | 3.928          | 11.301                | 26.699                |              |
| 2      | BCc1 nanoparticle low dose                       | 21       | 1.225          | 18.600                | 23.400                | 0.721        |
| 3      | BCc1 nanoparticle high dose                      | 14       | 4.899          | 4.398                 | 23.602                | 0.317        |
| 4      | Doxorubicin low dose                             | 14       | 6.547          | 1.169                 | 26.831                | 0.701        |
| 5      | Doxorubicin applicable dose                      | 23       | 3.928          | 15.301                | 30.699                | 0.609        |
| 6      | Mixture of BCc1 nanoparticle (low dose) and doxorubicin (low dose) | 29 | 23.568 | 0.000 | 75.192 | 0.749 |
| 7      | Mixture of BCc1 nanoparticle (high dose) and doxorubicin (applicable dose) | 9 | 2.449 | 4.199 | 13.801 | 0.431 |
| 8      | Mixture of BCc1 nanoparticle (low dose) and doxorubicin (applicable dose) | 12 | 1.309 | 9.434 | 14.566 | 0.201 |
| 9      | Mixture of BCc1 nanoparticle (high dose) and doxorubicin (low dose) | 34 | 5.237 | 23.735 | 44.265 | 0.040* |
| 10     | BCc1 nanoparticle orally used                    | 38       | 2.449          | 33.199                | 42.801                | 0.032*       |

**Note:** According to this table the groups 9 and 10 have different survival distributions with respect to the control group.

### Table 3 Mean survival time

| Groups                                           | Estimate | Standard error | Lower bound (95% CI) | Upper bound (95% CI) | Significance |
|--------------------------------------------------|----------|----------------|-----------------------|-----------------------|--------------|
| Control                                          | 19.571   | 3.709          | 12.302                | 26.841                |              |
| BCc1 nanoparticle low dose                       | 20.333   | 3.148          | 14.163                | 26.504                |              |
| BCc1 nanoparticle high dose                      | 15.167   | 4.086          | 7.158                 | 23.175                |              |
| Doxorubicin low dose                             | 20.143   | 5.599          | 9.168                 | 31.118                |              |
| Doxorubicin applicable dose                      | 20.143   | 5.309          | 15.184                | 25.102                |              |
| Mixture of BCc1 nanoparticle (low dose) and doxorubicin (low dose) | 21.429   | 4.582          | 12.448                | 30.409                |              |
| Mixture of BCc1 nanoparticle (high dose) and doxorubicin (applicable dose) | 16.000   | 4.099          | 7.966                 | 24.034                |              |
| Mixture of BCc1 nanoparticle (low dose) and doxorubicin (applicable dose) | 12.857   | 1.870          | 9.192                 | 16.522                |              |
| Mixture of BCc1 nanoparticle (high dose) and doxorubicin (low dose) | 32.000   | 3.359          | 25.416                | 38.584                |              |
| BCc1 nanoparticle used orally                    | 35.333   | 4.248          | 27.007                | 43.659                |              |

**Note:** Estimation is limited to the largest survival time if it is censored.
According to these figures, the cases in the groups which used BCc1 nanoparticle orally and the mixture of BCc1 nanoparticle high + doxorubicin low dose group had higher survival and lower hazard in respect to the cases of other groups.

**Discussion**

Cancer is still known as one of the most challenging global health-care issues around the world and is defined as the uncontrolled growth of cells. Accelerating cell division rates

![Hazard function graph](image)

**Figure 4** The hazard function in the groups which used BCc1 nanoparticle orally, and the mixture of BCc1 nanoparticle low dose and doxorubicin applicable dose showed a lower hazard than other groups.
or inhibiting normal controls on the system can be caused by mutations in cancer genes, such as cell cycle arrest or programmed cell death.\textsuperscript{36}

Doxorubicin is one of the most useful chemotherapy drugs in cancer therapy and Doxil\textsuperscript{\textregistered} (liposomal doxorubicin) is the first generation of nanomedicine approved clinically in the last two decades, yet the most common cytotoxic drug. It has a metabolic activity increasing free radical generation and oxidative stress induction, so it causes an imbalance between reactive oxygen species (ROS) and antioxidant enzymes, resulting in liver cell damage and cardiomyopathy in patients.\textsuperscript{10}
Omaira reported that a combination of selenium nanoparticles and doxorubicin is more effective on hepatocellular carcinoma than doxorubicin, when used alone. Kim found out that the consumption of erythropoietin is useful in the reduction of cardiomyopathy in patients treated with doxorubicin. Lamkanfi reported that Free DOX did not increase the mice survival significantly, while DOX-Lip increased the life-spans 35%. 

Nanochelating technology, patented as a new approach, has already proven its dramatic impact in the treatment of various diseases by different nanoparticles possessing effective properties. Additionally, it introduces a new generation of nanoparticles with therapeutic properties that do not need any carriers, unlike other nanoparticles loaded with drugs.

In vitro and in vivo studies showed that the BCc1 nanoparticle with iron chelating property has high potentials of inducing therapeutic behavior. Our previous study with FACS method proved that BCc1 nanostructure can decrease cell viability in cancer cells using apoptosis and arrest G1/S phase in treated cells. For the same reason, we investigated some gene expressions affecting apoptosis mechanism both in cancer and normal cells. It is proven that an increase in p53 decreases the expressions of the apoptosis-suppressing gene Bcl-2, while simultaneously stimulating an increase in Bax gene expression. P53 anticancer function is through apoptosis, genomic stability, and inhibition of angiogenesis, and it can also arrest growth by holding the cell cycle and activate DNA repair proteins when DNA sustains damage.

In this study, BCc1 nanoparticle significantly increased the ratio of Bax/Bcl-2 in cancer cells compared to normal cells. Also, we observed that it increased p53 in cancer cells but did not cause any changes in normal cells, so the results signified the presence of apoptosis pathway in cancer cells.

P21 is one of the main engines driving cellular transformation whose malfunction can result in losing proper control of the mammalian cell cycle. The different physiological responses caused by p21 are intertwined. For example, cell cycle arrest induced by p21 enhances DNA repair by providing the damaged DNA with enough time to get fixed before being sent to daughter cells, so this is a key path by which p21 exercises its anti-apoptotic activities. Some studies have demonstrated that RB performs in a pathway which is often inactivated in most human cancers. Successive activation of caspases has a key role in the execution-phase of cell apoptosis. This fact made us investigate Caspase7, which is a caspase (cysteine aspartate protease) protein family member. The analyses of tumor suppressor genes revealed that BCc1 nanoparticle treatment increased p21, RB, and Caspase7 gene expressions in cancer cells but did not increase healthy cells much.

The results of molecular analyses phase in the present study and flow cytometry in the previous one confirm each other, so these results subsequently prove the hypothesis that the BCc1 nanoparticle can intelligently activate the apoptosis cycle in cancer cells and then stop them, yet the apoptosis cycle does not get activated in healthy cells when used at a favorable dose.

Our previous animal study performed on breast cancer-bearing Balb/c mice showed that treating mice with the BCc1 nanoparticle, when used intraperitoneally, reduces tumor cells growth and increases survival compared to a control group, but in the present study it was attempted to investigate its effect when used orally, the results of which showed that median and mean survival times in the BCc1 nanoparticle group increased compared to other groups.

The comparison of the mixture of BCc1 nanoparticle and doxorubicin in four combinations [BCc1 nanoparticle (high dose) and doxorubicin (applicable dose), BCc1 nanoparticle (low dose) and doxorubicin (low dose), BCc1 nanoparticle (applicable dose) and doxorubicin (low dose), and BCc1 nanoparticle (low dose) and doxorubicin (applicable dose)] revealed that the mixture of BCc1 nanoparticle in high dose and doxorubicin in low dose led to a higher median and mean survival times. Therefore, it can be claimed that there is a synergism effect between BCc1 nanoparticle and doxorubicin.

Currently, scientists apply various technologies to reduce the toxicity of chemotherapy agents and increase their efficacy, especially by nanotechnology that improves the bioavailability of medicines and “thus enhances efficacy without any need for higher doses”. Therefore, nanotechnology can result in a difference in patients and the clinical outcomes, as the maximum tolerated dose of the active agent can be improved by preventing tolerability problems.

According to the results of the present study, survival could be increased by the BCc1 nanoparticle mixture, while the doxorubicin dose was one-fiftieth of its murine applicable dose. So this is a novel approach having the potential to be evaluated and optimized in further studies.

**Conclusion**

Although doxorubicin dose was reduced by 50 times, survival increased by 48% compared to control, so it can be claimed that this favorable result was due to the mixture...
of doxorubicin with the BCc1 nanoparticle, and we can achieve a new chemotherapy regime by reducing the doxorubicin dose. Moreover, the BCc1 nanoparticle can be regarded as an independent medicine for the treatment of cancer by complementary studies in the future.

Acknowledgments
The authors appreciate the support of Shahid Beheshti University of Medical Sciences, Cancer Research Centre at Shahid Beheshti University of Medical Sciences and Department of Research and Development at Sodour Ahrar Shargh Company, Tehran, Iran. This paper is part of Maryam Hafizi’s PhD thesis, named “Evaluation of nanochelating based nanomedicine, BCc1, using cellular and animal model of cancer and then safety and efficacy study in metastatic and non-metastatic Gastric Cancer patients”.

Disclosure
Mr Mohammad Hassan Nazaran reports a patent US8288587B2 with royalties paid. The authors report no other conflicts of interest in this work.

References
1. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193. doi:10.3322/caac.21395
2. Gupta SK, Garg A, Bar C, et al. Quaking inhibits doxorubicin-mediated cardiotoxicity through regulation of cardiac circular RNA expression. Cir. Res. 2018;122(2):246-254. doi:10.1161/CIRCRESAHA.117.11335
3. Liu Y, Jia Q, Guo Q, Wei W, Zhou J. Simultaneously activating highly selective ratiometric MRI and synergistic therapy in response to intra-tumoral oxidability and acidity. Biomaterials. 2018;180:104–116. doi:10.1016/j.biomaterials.2018.07.025
4. Zhu X, Li J, Qiu X, Liu Y, Feng W, Li F. Upconversion nanocomposite for programming combination cancer therapy by precise control of microscopic temperature. Nat Commun. 2018;9(1):2176. doi:10.1038/s41467-018-04571-4
5. Xinyin Liu QG, Zhu X, Feng W, et al. Optimization of prussian blue coated NaDFy4: %Lu Nanocomposites for multifunctional imaging-guided photothermal therapy. Adv Funct. 2016;26;5120. doi:10.1002/adfm.201601478
6. Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanocomposite of synergistic drug combinations for cancer therapy - strategies and perspectives. J Control Release. 2016;240:489–503. doi:10.1016/j.jconrel.2016.06.012
7. Johnson-Arbor K, Dubey R. Doxorubicin. In: StatPeaars. Treasure Island, FL; 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459223. Last accessed 31 May 2019.
8. Xu YC, Liu X, Li M, et al. A novel mechanism of doxorubicin resistance and tumorigenesis mediated by MicroRNA-501-5p-suppressed BLID. Mol Ther Nucleic Acids. 2018;12:578–590. doi:10.1016/j.omtn.2018.06.011
9. Iwamoto T. Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol Pharm Bull. 2013;36(5):715–718. doi:10.1248/bpb.b12-01102
10. Abd El-Moneim OM, Abd El-Rahim AH, Hafiz NA. Evaluation of selenium nanoparticles and doxorubicin effect against hepatocellular carcinoma rat model cyto genetic toxicity and DNA damage. Toxicol Rep. 2018;5:771–776. doi:10.1016/j.toxrep.2018.07.003
11. Li S, Yuan S, Zhao Q, Wang B, Wang X, Li K. Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it. Biomed Pharmacother. 2018;100:441–447. doi:10.1016/j.biopha.2018.02.055
12. Available from: https://www.rxlist.com/consumer_doxorubicin_adria-mycin/drugs-condition.htm
13. Grigorian A, O'Brien CB. Hepatotoxicity secondary to chemotherapy. J Clin Transl Hepatol. 2014;2(2):95–102. doi:10.4218/JCTH.2014.00011
14. Balsari A, Menard S, Colnaghi MI, Ghione M. Anti-drug monoclonal antibodies antagonize toxic effect more than anti-tumor activity of doxorubicin. Int J Cancer. 1991;47(6):889–892.
15. Hare JJ, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25–38. doi:10.1016/j.addr.2016.04.025
16. Zhao CY, Cheng R, Yang Z, Tian ZM. Nanotechnology for cancer therapy based on chemotherapy. Molecules. 2018;23:4.
17. Sharma M, Pandey C, Sharma N, Kamal MA, Sayeed U, Akhtar S. Cancer nanotechnology - an excursion on drug delivery systems. Anticancer Agents Med Chem. 2018;18(15):2078–2092.
18. Nazaran MH. Chelate compounds. Google Patents US8288587B2. 2012.
19. Fakharzadeh S, Sahraian MA, Hafizi M, et al. The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitis C57/BL6 mice. Int J Nanomedicine. 2014;9:3841–3853. doi:10.2147/IJN.S64630
20. Maghsoudi A, Fakharzadeh S, Hafizi M, et al. Neuroprotective effects of three different sizes nanochelating based nano complexes in MPP(+) induced neurotoxicity. Apoptosis. 2015;20(3):298–309. doi:10.1007/s10495-014-1069-x
21. Hafizi M, Hajarizadeh A, Atashi A, et al. Nanochelating based nanocomplex, GFc7, improves quality and quantity of human mesenchymal stem cells during in vitro expansion. Stem Cell Res Ther. 2015;6:226. doi:10.1186/s13287-015-0216-9
22. Kalanaky S, Hafizi M, Fakharzadeh S, et al. BCc1, the novel anti-neoplastic nanocomplex, showed potent antitumor effects in vitro and in vivo. Drug Des Devel Ther. 2016;10:59–70. doi:10.2147/DDDT.S89694
23. Sherr CJ. Principles of tumor suppression. Cell. 2004;116(2):225–246.
24. Feyzian A, Serrano M, p53: guardian of the genome and policeman of the oncopgenes. Cell Cycle. 2007;6(9):1006–1010. doi:10.4161/cc.6.9.4211
25. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the suppression of BLID. Ther. 1995;52(2):517–5190.
26. Romanov Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB. Chelate compounds. Google Patents US8288587B2. 2012.
27. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820–823. doi:10.1073/pnas.68.4.820
28. Mischianzi C, Puviani AC, Brogli M, et al. Modulation of pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) gene expression in isolated porcine hepatocytes perfused within a radial-flow bioreactor at low-temperature storing. Int J Artif Organs. 2003;26(2):139–148.
29. Fan TJ, Han LH, Cong RS, Liang J. Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai). 2005;37(11):719–727.
30. Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB. Doxorubicin and paclitaxel enhance the antitumor efﬁcacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004;6(4):R275–83. doi:10.1186/bcr787
31. Bandyopadhyay A, Wang L, Agyin J, et al. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. *PLoS One.* 2010;5(4):e10365. doi:10.1371/journal.pone.0010365

32. Baliga MS, Meleth S, Katiyar SK. Growth inhibitory and antmetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. *Clin Cancer Res.* 2005;11(5):1918–1927. doi:10.1158/1078-0432.CCR-04-1976

33. Gharibi B, Hughes FJ. Effects of medium supplements on proliferation, differentiation potential, and in vitro expansion of mesenchymal stem cells. *Stem Cells Transl Med.* 2012;1(11):771–782. doi:10.5966/sctm.2010-0031

34. Hafizi M, Bakhshandeh B, Soleimani M, Atashi A. Exploring the enkephalinergic differentiation potential in adult stem cells for cell therapy and drug screening implications. *In Vitro Cell Dev Biol Anim.* 2012;48(9):562–569. doi:10.1007/s11626-012-9546-4

35. Hejazi E, Nasrollahzadeh J, Fatemi R, et al. Effects of combined soy isoflavone extract and docetaxel treatment on murine 4T1 breast tumor model. *Avicenna J Med Biotechnol.* 2015;7(1):16–21.

36. Bosch FX, Ribes J, Diaz M, Clères R. Primary liver cancer: worldwide incidence and trends. *Gastroenterology.* 2004;127(5 Suppl 1):S5–S16

37. Kim KH, Oudit GY, Backx PH. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. *J Pharmacol Exp Ther.* 2008;324(1):160–169. doi:10.1124/jpet.107.125773

38. Mayhew EG, Goldrosen MH, Vaage J, Rustum YM. Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. *J Natl Cancer Inst.* 1987;78(4):707–713.

39. Lamkanfi M, Kanneganti TD. Caspase-7: a protease involved in apoptosis and inflammation. *Int J Biochem Cell Biol.* 2010;42(1):21–24. doi:10.1016/j.biocel.2009.09.013

40. Tran S, Degiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. *Clin Transl Med.* 2017;6(1):44. doi:10.1186/s40169-017-0175-0

41. Tian J, Min Y, Rodgers Z, et al. Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer. *Nanomedicine.* 2017;13(3):1301–1307. doi:10.1016/j.nano.2016.11.007